# CureVac

mRNA治疗先驱，被BioNTech收购（2025年1月）——CV8102佐剂和优化mRNA构建物；第二代自扩增mRNA技术已授权多家合作伙伴；收购后存在整合风险。

Source: https://cn.bioecon.ru/companies/curevac/
Updated: 2026-06-19

- 国家: Germany
- 营收: ~$50M
- 员工: ~200 emp

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 截至2025年3月31日现金头寸为€4.383亿；截至2024年12月31日现金头寸为€4.817亿 | https://www.curevac.com/wp-content/uploads/2025/04/20250410-CureVac-Investor-Handout.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250410-PR-CureVac-Q4-FY-Results-EN.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250417_CureVac-Transcript-Financial-Results-Fourth-Quarter-and-Full-Year-2024.pdf, https://www.curevac.com/wp-content/uploads/2025/05/20250520-CureVac-Investor-Handout.pdf |
| 生产基地 | 德国图宾根（Tübingen，总部及生产基地），另在荷兰、比利时、瑞士和美国设有业务 | https://synapse.patsnap.com/article/what-is-the-research-and-development-focus-of-curevac, https://www.curevac.com/wp-content/uploads/2025/04/20250410-CureVac-Investor-Handout.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250410-PR-CureVac-Q4-FY-Results-EN.pdf, https://www.curevac.com/wp-content/uploads/2025/05/CureVac-N.V._Dutch-Board-Report-Independent-Auditors-Report-FY2024-signed.pdf |
| 认证 | The RNA Printer® 的 mRNA 构建体生产许可证（2023年11月）、原料药框架生产许可证（2023年12月）及肿瘤学更新生产许可证（2024年7月） | https://www.curevac.com/wp-content/uploads/2025/05/CureVac-N.V._Dutch-Board-Report-Independent-Auditors-Report-FY2024-signed.pdf |
| 营收 | 2024全年€5.352亿；2024年第四季度€1450万 | https://www.curevac.com/wp-content/uploads/2025/04/20250410-CureVac-Investor-Handout.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250410-PR-CureVac-Q4-FY-Results-EN.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250417_CureVac-Transcript-Financial-Results-Fourth-Quarter-and-Full-Year-2024.pdf, https://www.curevac.com/wp-content/uploads/2025/05/CureVac-N.V._Dutch-Board-Report-Independent-Auditors-Report-FY2024-signed.pdf |
| 员工人数 | 2024年平均员工人数约为1,088人；公司在2024年完成了30%的裁员 | https://www.curevac.com/wp-content/uploads/2025/04/20250410-CV-Q4-FY-Earnings-Call-presentation.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250410-CureVac-Investor-Handout.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250417_CureVac-Transcript-Financial-Results-Fourth-Quarter-and-Full-Year-2024.pdf, https://www.curevac.com/wp-content/uploads/2025/05/20250520-CureVac-Investor-Handout.pdf, https://www.curevac.com/wp-content/uploads/2025/05/CureVac-N.V._Dutch-Board-Report-Independent-Auditors-Report-FY2024-signed.pdf |
| 产能 | 已降低商业规模大规模生产的优先级；重点转向利用The RNA Printer®和现有GMP设施（GMP III + GMP IV）进行小规模临床试验供应 | https://www.curevac.com/wp-content/uploads/2025/04/20250410-CureVac-Investor-Handout.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250410-PR-CureVac-Q4-FY-Results-EN.pdf, https://www.curevac.com/wp-content/uploads/2025/05/CureVac-N.V._Dutch-Board-Report-Independent-Auditors-Report-FY2024-signed.pdf |

独立来源: synapse.patsnap.com

## 技术

- [mRNA 平台与 LNP 递送](https://cn.bioecon.ru/technology/mrna-platforms-lnp-delivery/)